# Vanda Pharmaceuticals Inc.: financial statements, quarterly

VNDA · Nasdaq · CIK 1347178 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vnda.md) · [Financials](/companies/vnda/financials.md) · [Filings](/companies/vnda/filings.md) · [Insiders](/companies/vnda/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/vnda/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [45.3 d](/filings/0001628280-26-007460.md) | [47.5](/filings/0001628280-25-023448.md) | [50.5](/filings/0001628280-25-036861.md) | [47.7](/filings/0001628280-25-047317.md) | [53.2 d](/filings/0001628280-26-007460.md) | [50.0](/filings/0001628280-26-031667.md) | [52.6](/filings/0001628280-26-053855.md) | [56.3](/filings/0001347178-26-000002.md) | [57.2 d](/filings/0001628280-26-007460.md) | [51.7](/filings/0001628280-26-031667.md) | [50.5](/filings/0001628280-26-053855.md) | [69.8](/filings/0001347178-26-000002.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [24.3 d](/filings/0001628280-26-007460.md) | [21.2](/filings/0001628280-25-023448.md) | [16.7](/filings/0001628280-25-036861.md) | [16.8](/filings/0001628280-25-047317.md) | [19.8 d](/filings/0001628280-26-007460.md) | [35.7](/filings/0001628280-26-031667.md) | [22.0](/filings/0001628280-26-053855.md) | [22.6](/filings/0001347178-26-000002.md) | [29.0 d](/filings/0001628280-26-007460.md) | [28.4](/filings/0001628280-26-031667.md) | [37.0](/filings/0001628280-26-053855.md) | [27.6](/filings/0001347178-26-000002.md) |
| Selling, general and administrative | $m | [23.6 d](/filings/0001628280-26-007460.md) | [30.1](/filings/0001628280-25-023448.md) | [39.5](/filings/0001628280-25-036861.md) | [37.6](/filings/0001628280-25-047317.md) | [39.3 d](/filings/0001628280-26-007460.md) | [50.1](/filings/0001628280-26-031667.md) | [64.6](/filings/0001628280-26-053855.md) | [60.3](/filings/0001347178-26-000002.md) | [63.0 d](/filings/0001628280-26-007460.md) | [68.4](/filings/0001628280-26-031667.md) | [71.8](/filings/0001628280-26-053855.md) | [59.6](/filings/0001347178-26-000002.md) |
| Operating income | $m | [(7.1) d](/filings/0001628280-26-007460.md) | [(9.2)](/filings/0001628280-25-023448.md) | [(10.1)](/filings/0001628280-25-036861.md) | [(11.0)](/filings/0001628280-25-047317.md) | [(10.3) d](/filings/0001628280-26-007460.md) | [(41.0)](/filings/0001628280-26-031667.md) | [(38.5)](/filings/0001628280-26-053855.md) | [(31.3)](/filings/0001347178-26-000002.md) | [(40.4) d](/filings/0001628280-26-007460.md) | [(50.2)](/filings/0001628280-26-031667.md) | [(63.8)](/filings/0001628280-26-053855.md) | [(23.5)](/filings/0001347178-26-000002.md) |
| Income tax | $m | [0.7 d](/filings/0001628280-26-007460.md) | [(0.5)](/filings/0001628280-25-023448.md) | [(1.0)](/filings/0001628280-25-036861.md) | [(0.9)](/filings/0001628280-25-047317.md) | [(1.6) d](/filings/0001628280-26-007460.md) | [(7.9)](/filings/0001628280-26-031667.md) | [(7.7)](/filings/0001628280-26-053855.md) | [(5.8)](/filings/0001347178-26-000002.md) | [103 d](/filings/0001628280-26-007460.md) | [0.1](/filings/0001628280-26-031667.md) | [0.1](/filings/0001628280-26-053855.md) | [0.2](/filings/0001347178-26-000002.md) |
| Net income | $m | [(2.4) d](/filings/0001628280-26-007460.md) | [(4.1)](/filings/0001628280-25-047317.md) | [(4.5)](/filings/0001628280-25-047317.md) | [(5.3)](/filings/0001628280-25-047317.md) | [(4.9) d](/filings/0001628280-26-007460.md) | [(29.5)](/filings/0001347178-26-000002.md) | [(27.2)](/filings/0001347178-26-000002.md) | [(22.6)](/filings/0001347178-26-000002.md) | [(141) d](/filings/0001628280-26-007460.md) | [(48.6)](/filings/0001347178-26-000002.md) | [(62.5)](/filings/0001347178-26-000002.md) | [(22.6)](/filings/0001347178-26-000002.md) |
| Diluted EPS | $ per share | not reported | [(0.07)](/filings/0001628280-25-023448.md) | [(0.08)](/filings/0001628280-25-036861.md) | [(0.09)](/filings/0001628280-25-047317.md) | not reported | [(0.50)](/filings/0001628280-26-031667.md) | [(0.46)](/filings/0001628280-26-053855.md) | [(0.38)](/filings/0001347178-26-000002.md) | not reported | [(0.82)](/filings/0001628280-26-031667.md) | [(1.04)](/filings/0001628280-26-053855.md) | [(0.37)](/filings/0001347178-26-000002.md) |
| Basic EPS | $ per share | not reported | [(0.07)](/filings/0001628280-25-023448.md) | [(0.08)](/filings/0001628280-25-036861.md) | [(0.09)](/filings/0001628280-25-047317.md) | not reported | [(0.50)](/filings/0001628280-26-031667.md) | [(0.46)](/filings/0001628280-26-053855.md) | [(0.38)](/filings/0001347178-26-000002.md) | not reported | [(0.82)](/filings/0001628280-26-031667.md) | [(1.04)](/filings/0001628280-26-053855.md) | [(0.37)](/filings/0001347178-26-000002.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [136](/filings/0001628280-25-005761.md) | [125](/filings/0001628280-25-023448.md) | [103](/filings/0001628280-25-036861.md) | [100](/filings/0001628280-25-047317.md) | [102](/filings/0001628280-26-007460.md) | [112](/filings/0001628280-26-031667.md) | [81.0](/filings/0001628280-26-053855.md) | [70.0](/filings/0001347178-26-000002.md) | [84.9](/filings/0001347178-26-000002.md) | [54.0](/filings/0001628280-26-031667.md) | [55.9](/filings/0001628280-26-053855.md) | [61.9](/filings/0001347178-26-000002.md) |
| Current assets | $m | [433](/filings/0001628280-25-005761.md) | [439](/filings/0001628280-24-021952.md) | [439](/filings/0001628280-24-033866.md) | [432](/filings/0001628280-24-045970.md) | [439](/filings/0001628280-26-007460.md) | [408](/filings/0001628280-25-023448.md) | [395](/filings/0001628280-25-036861.md) | [367](/filings/0001628280-25-047317.md) | [347](/filings/0001347178-26-000002.md) | [293](/filings/0001628280-26-031667.md) | [264](/filings/0001628280-26-053855.md) | [238](/filings/0001347178-26-000002.md) |
| Total assets | $m | [648](/filings/0001628280-25-005761.md) | [653](/filings/0001628280-24-021952.md) | [651](/filings/0001628280-24-033866.md) | [645](/filings/0001628280-24-045970.md) | [656](/filings/0001628280-26-007460.md) | [632](/filings/0001628280-25-023448.md) | [625](/filings/0001628280-25-036861.md) | [601](/filings/0001628280-25-047317.md) | [489](/filings/0001347178-26-000002.md) | [434](/filings/0001628280-26-031667.md) | [412](/filings/0001628280-26-053855.md) | [382](/filings/0001347178-26-000002.md) |
| Current liabilities | $m | [87.7](/filings/0001628280-25-005761.md) | [93.3](/filings/0001628280-24-021952.md) | [93.8](/filings/0001628280-24-033866.md) | [89.1](/filings/0001628280-24-045970.md) | [100.0](/filings/0001628280-26-007460.md) | [104](/filings/0001628280-25-023448.md) | [121](/filings/0001628280-25-036861.md) | [118](/filings/0001628280-25-047317.md) | [145](/filings/0001347178-26-000002.md) | [136](/filings/0001628280-26-031667.md) | [164](/filings/0001628280-26-053855.md) | [155](/filings/0001347178-26-000002.md) |
| Total liabilities | $m | [104](/filings/0001628280-25-005761.md) | [109](/filings/0001628280-24-021952.md) | [109](/filings/0001628280-24-033866.md) | [104](/filings/0001628280-24-045970.md) | [118](/filings/0001628280-26-007460.md) | [121](/filings/0001628280-25-023448.md) | [138](/filings/0001628280-25-036861.md) | [135](/filings/0001628280-25-047317.md) | [162](/filings/0001347178-26-000002.md) | [153](/filings/0001628280-26-031667.md) | [192](/filings/0001628280-26-053855.md) | [182](/filings/0001347178-26-000002.md) |
| Shareholders' equity | $m | [545](/filings/0001628280-26-007460.md) | [544](/filings/0001628280-25-047317.md) | [543](/filings/0001628280-25-047317.md) | [541](/filings/0001628280-25-047317.md) | [539](/filings/0001347178-26-000002.md) | [511](/filings/0001347178-26-000002.md) | [486](/filings/0001347178-26-000002.md) | [466](/filings/0001347178-26-000002.md) | [327](/filings/0001347178-26-000002.md) | [281](/filings/0001347178-26-000002.md) | [220](/filings/0001347178-26-000002.md) | [200](/filings/0001347178-26-000002.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(3.7) d](/filings/0001628280-26-007460.md) | [7.6](/filings/0001628280-25-023448.md) | [(6.9) d](/filings/0001628280-25-036861.md) | [(14.6) d](/filings/0001628280-25-047317.md) | [(1.8) d](/filings/0001628280-26-007460.md) | [(33.1)](/filings/0001628280-26-031667.md) | [(15.3) d](/filings/0001628280-26-053855.md) | [(31.6) d](/filings/0001347178-26-000002.md) | [(29.4) d](/filings/0001628280-26-007460.md) | [(50.2)](/filings/0001628280-26-031667.md) | [(31.1) d](/filings/0001628280-26-053855.md) | [(28.4) d](/filings/0001347178-26-000002.md) |
| Capital expenditure | $m | [0.3 d](/filings/0001628280-26-007460.md) | [0.0](/filings/0001628280-25-023448.md) | [0.1 d](/filings/0001628280-25-036861.md) | [0.2 d](/filings/0001628280-25-047317.md) | [0.2 d](/filings/0001628280-26-007460.md) | [0.4](/filings/0001628280-26-031667.md) | [0.3 d](/filings/0001628280-26-053855.md) | [0.2 d](/filings/0001347178-26-000002.md) | [0.1 d](/filings/0001628280-26-007460.md) | [0.2](/filings/0001628280-26-031667.md) | [0.2 d](/filings/0001628280-26-053855.md) | [0.3 d](/filings/0001347178-26-000002.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [57.4](/filings/0001628280-24-021952.md) | [57.5](/filings/0001628280-24-033866.md) | [57.6](/filings/0001628280-24-045970.md) | [57.8](/filings/0001628280-25-023448.md) | [58.2](/filings/0001628280-25-036861.md) | [58.3](/filings/0001628280-25-047317.md) | [58.5](/filings/0001628280-26-031667.md) | [59.0](/filings/0001628280-26-053855.md) | [59.1](/filings/0001347178-26-000002.md) | [59.5](/filings/0001628280-26-031667.md) | [60.2](/filings/0001628280-26-053855.md) | [60.5](/filings/0001347178-26-000002.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 60,469,687 at 2026-10-22, from the cover of the [10-Q filed 2026-10-29](/filings/0001347178-26-000002.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 08:08 ET. No prices; not investment advice.